Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00716534 · ClinicalTrials.gov registry record · Phase 2
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT00716534 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 145 participants.
The verdict
NCT00716534, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG ABT-869
- DRUG Placebo for ABT-869
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00716534
The ClinicalTrials.gov registry entry for NCT00716534 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00716534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00716534 about?
NCT00716534 is a clinical study titled "Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.
What is the current status of trial NCT00716534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2008-06. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00716534?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), ABT-869 (DRUG), Placebo for ABT-869 (DRUG).
Who is sponsoring clinical trial NCT00716534?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.